Dynavax Technologies (NASDAQ:DVAX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAXFree Report) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $29.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Dynavax Technologies’ FY2026 earnings at $0.32 EPS.

Separately, The Goldman Sachs Group lowered their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Dynavax Technologies presently has an average rating of “Moderate Buy” and a consensus price target of $23.67.

View Our Latest Analysis on Dynavax Technologies

Dynavax Technologies Trading Up 0.3 %

NASDAQ:DVAX opened at $10.95 on Tuesday. Dynavax Technologies has a 1 year low of $9.74 and a 1 year high of $15.15. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The stock has a fifty day moving average price of $11.05 and a two-hundred day moving average price of $11.27. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of 182.50 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAXGet Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The business had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. During the same quarter last year, the firm posted $0.03 EPS. As a group, sell-side analysts anticipate that Dynavax Technologies will post 0.16 earnings per share for the current fiscal year.

Institutional Trading of Dynavax Technologies

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its stake in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,685 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Dynavax Technologies in the second quarter valued at $140,000. Sanctuary Advisors LLC acquired a new stake in shares of Dynavax Technologies during the second quarter valued at $182,000. XTX Topco Ltd purchased a new stake in Dynavax Technologies during the 2nd quarter worth about $184,000. Finally, Duality Advisers LP acquired a new position in Dynavax Technologies in the 1st quarter valued at about $227,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

(Get Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Featured Stories

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.